How Vitamin C works:
Chemotherapy kills both cancer cells and white blood cells. White blood cells are the 'soldiers' in the body that uses H2O2 (Hydrogen Peroxide) as weapons to kill bad cells such as cancer cells, bad bacteria, or virus.
These bad cells have iron in them, and they replicate by means of iron which is its food.
Abstaining from iron-rich food such as meat is necessary to keep these bad cells from replicating.
Example:
This person made her father eat vegetarian food and as a result was able to make the cancer disappear. But as soon as he started eating meat once or twice a week for 3 months, the cancer grew 2 cm. https://www.youtube.com/shorts/H2MY9soJhys
H2O2 kills these cells by reacting with the iron in them, called the Fenton reaction. The H2O2 then breaks down into oxygen and water.
When you take Vitamin C, half of it is converted into H2O2 and the other half into oxalate. (sufficient water needs to be taken with Vitamin C to dilute this oxalate). So it provides the much needed H2O2 the body needs to combat cancer cells when there is a shortage of white blood cells as a result of chemotherapy killing them.
Orally taken Vitamin C (tablets, capsule) may be good enough to prevent very tiny cancer from getting bigger, but are too weak in case of fighting an ongoing cancer. For that IVC (Intravenous Vitamin C) Therapy must be used. But even this is usually recommended not as a standalone, but as an addition to the standard chemoradiation therapy.
Orally taken Vitamin C also kills the biofilms in your gut to improve the gut microbiome, which helps the immune system.
Homemade water-kefir could be used to replenish the gut biome killed by chemotherapy. (a typical kefir may be dangerous in that as a dairy product it contains the protein casein which promotes growth of cancer cells, especially when exceeding 10% of total calorie.)
Source on dairy promoting cancer: Colin Campbell, author the The China Study.
IVC therapy is being recognized even in mainstream institutions in recent years:
- Pancreatic cancer (metastatic/stage 4): A randomized phase 2 trial (published November 2024 in Redox Biology) showed that adding high-dose IVC (75 g infusions three times weekly) to standard chemotherapy (gemcitabine + nab-paclitaxel) doubled median overall survival from ~8 months (control group, aligning with historical data) to 16 months. Progression-free survival also nearly doubled (from ~3.9–4 months to ~6.2 months). The trial was stopped early due to strong ethical signals of benefit. Results were announced publicly around November 11–14, 2024, with coverage in outlets like UI's own news, Healio, and others extending into 2025.
- Glioblastoma (aggressive brain cancer): A phase 2 trial's results were published in early 2024 (in Clinical Cancer Research). Adding high-dose IVC to standard chemoradiation (temozolomide + radiation) extended median survival by about 5 months compared to historical/expected outcomes with standard care alone (e.g., prior phase 1 data from ~2019 showed ~18 months median OS vs. historical ~14–15 months). Earlier phase 1 safety/efficacy hints dated back to publications around 2017–2019.
This represents a shift in some mainstream oncology circles: while IVC isn't yet standard care or FDA-approved for cancer, these NCI-funded, randomized trials at a major U.S. university hospital provide credible evidence supporting its adjunctive use in hard-to-treat cancers. Ongoing or related trials (e.g., lung cancer nearing completion) continue this line of research.